$25.13
-0.13 (-0.51%)
Open$25.51
Previous Close$25.26
Day High$26.14
Day Low$24.67
52W High$28.00
52W Low$6.57
Volume—
Avg Volume649.6K
Market Cap1.19B
P/E Ratio—
EPS$-5.40
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+45.9% upside
Current
$25.13
$25.13
Target
$36.67
$36.67
$19.65
$36.67 avg
$47.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 85.08M | 76.59M | 82.32M |
| Net Income | 21.83M | 19.00M | 17.76M |
| Profit Margin | 25.7% | 24.8% | 21.6% |
| EBITDA | 33.39M | 28.41M | 32.89M |
| Free Cash Flow | 16.91M | 11.51M | 18.65M |
| Rev Growth | +15.3% | +2.7% | +8.4% |
| Debt/Equity | 0.18 | 0.16 | 0.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |